Muscle Pain Management in Muscular Dystrophy
For muscle pain in muscular dystrophy patients, routinely assess and address pain as a core component of care, using non-opioid analgesics (NSAIDs) as first-line pharmacological treatment, combined with education, self-management strategies, and low-intensity aerobic exercise.
Pain Assessment and Recognition
Pain is extremely common in muscular dystrophy and significantly impacts quality of life. Treating physicians should routinely inquire about pain at every clinical visit 1. Recent surveillance data shows moderate pain occurs in 34% of all MD patients, with variation by type (13%-53%), and pain is particularly prevalent in FSHD where 88.6% report pain 2, 3. The most frequent pain locations are shoulders and lower back 3.
Key Clinical Points:
- Pain strongly correlates with impaired mobility 2
- Chronic pain (present in approximately 30% of patients) has severe negative impact on all quality of life domains 3
- Women may experience greater deterioration in emotional aspects of QoL related to pain 4
Pharmacological Management Algorithm
First-Line: Non-Opioid Analgesics
NSAIDs should be the primary pharmacological intervention for muscle pain in MD patients 5. Evidence from mdx mouse models demonstrates NSAIDs (aspirin, ibuprofen, parecoxib) effectively:
- Ameliorate muscle morphology
- Reduce macrophage infiltration and necrosis
- Decrease COX-2 expression and inflammatory cytokines
This suggests inflammation plays a crucial role in MD progression, making anti-inflammatory treatment mechanistically sound 5.
Opioid Considerations
Avoid routine opioid use for chronic muscle pain in MD patients. While surveillance data shows both non-opioid and opioid medications are prescribed (34% receive both classes), the general MSK pain guideline evidence strongly discourages opioids for chronic pain 6. Among MD patients prescribed pain medications:
- 57% receive non-opioids only as first medication
- Most prescriptions continue longer than 1 year (>85%) 2
Common Pitfall: Do not reflexively prescribe opioids for chronic MD-related pain. The evidence for chronic MSK pain management argues against this approach 6.
Glucocorticoids for DMD
For Duchenne muscular dystrophy specifically, glucocorticoids (prednisone 0.75 mg/kg/day or deflazacort 0.9 mg/kg/day) are the only medications that slow muscle strength decline 7. While primarily prescribed for disease modification rather than pain control, their anti-inflammatory effects may provide pain relief as a secondary benefit 5.
Non-Pharmacological Management
Exercise Prescription
Encourage low-intensity aerobic exercise in MD patients 1. Available evidence suggests aerobic exercise is:
- Safe in FSHD and likely other MD types
- Potentially beneficial for function
- Should be low-intensity to avoid overwork injury
Education and Self-Management
Apply principles from high-quality MSK pain guidelines 6:
- Provide education about the condition and pain mechanisms
- Offer self-management programs
- Set realistic functional goals
- Address psychosocial factors (anxiety, depression) that amplify pain perception
Important Caveat: While psychosocial assessment is universally recommended, specific psychological interventions for MD-related pain lack robust evidence in this population 6.
Age-Specific Considerations
Pain medication prescription patterns differ dramatically by age 2:
- Under 20 years: <15% prescribed pain medications
- 20 years and older: 31.1%-40.2% prescribed pain medications
This suggests either undertreatment in younger patients or different pain patterns with disease progression. Actively assess pain in adolescents and young adults, as they may not spontaneously report it.
Monitoring and Follow-Up
- Assess pain at routine 6-month clinic appointments 7
- Monitor for medication side effects, particularly with chronic NSAID use (GI, renal, cardiovascular risks)
- Track functional impact of pain on daily activities
- Adjust treatment based on pain severity and functional limitations
What NOT to Do
Based on general MSK pain guidelines 6:
- Do not offer paracetamol/acetaminophen as sole medication (insufficient efficacy)
- Avoid passive treatments without evidence (e.g., TENS, laser therapy)
- Do not pursue interventional procedures (injections) for muscle pain in MD
The evidence strongly supports a proactive, multimodal approach prioritizing NSAIDs, exercise, and self-management over passive treatments or opioids.